Valion Bio, Inc. filed an amended 8-K to disclose the final certified voting results from its Special Meeting of Stockholders held on August 14, 2026. The company reported that stockholders approved Proposal No. 1, granting the Board discretionary authority to effect a reverse stock split of common shares at a ratio between 1-for-5 and 1-for-50 within twelve months. This proposal received 1,243,530 votes in favor against 697,127 opposed, with approximately 48.21% of outstanding common shares represented. Proposal No. 2 to adjourn the meeting was also approved but not utilized as the primary objective was achieved. Valion Bio, Inc. operates in the biotechnology industry.

Valion Bio, Inc. announced the termination of CEO Michael K. Handley effective August 16, 2026, and appointed CFO Lisa Wolf as Chief Operating Officer on the same date. The company entered into a letter agreement with 3i, LP to issue 1,500 shares of Series B Preferred Stock at $1,000 per share for an aggregate purchase price of $1,500,000, closing around August 17, 2026. Concurrently, a royalty agreement was executed granting investors 5% of gross revenue from subsidiary Velocity Bioworks, Inc. for ten years. At a Special Meeting on August 14, 2026, shareholders approved granting the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-50 within twelve months. Valion Bio, Inc. operates in the biotechnology sector.